Highlights

  • Morgan Stanley lowered ZBIO’s rating while maintaining formal price objective coverage.
  • Analyst opinions on Zenas BioPharma remain varied across major research firms.
  • Insider and institutional activity continued during recent quarters.

Zenas BioPharma (NASDAQ:ZBIO) was downgraded by Morgan Stanley, which shifted its rating on the stock from “overweight” to “equal weight” in a research note issued earlier this week. The brokerage maintained a price objective of USD 19.00 while adjusting its overall stance on the clinical-stage biotechnology company. The revision places Morgan Stanley among a broad range of analysts currently tracking the stock with differing assessments.

Other research firms have also updated their views on Zenas BioPharma in recent months. Wall Street Zen raised its rating from “sell” to “hold” in early November. Weiss Ratings, by contrast, reiterated a “sell (D-)” assessment toward the end of December. Coverage initiations and revisions from larger brokerages added further dispersion, with Evercore ISI, Wedbush, and Citigroup all assigning higher-rated classifications alongside published price targets. Based on compiled analyst data, the stock currently carries a consensus classification described as “Moderate Buy,” reflecting the mix of bullish, neutral, and cautious outlooks.

Insider trading disclosures indicate notable purchasing activity during the last reported quarter. Director Hongbo Lu acquired more than 260,000 shares at an average price of USD 19.00 per share, substantially increasing his ownership position. Director Patrick G. Enright also reported the purchase of over 105,000 shares at the same average price, adding incrementally to an already sizable holding. In aggregate, insiders reported buying more than 923,000 shares during the quarter, with corporate insiders collectively holding about 16.5% of outstanding shares.

Institutional investors have also adjusted their exposure. Federated Hermes Inc. expanded its position significantly during the second quarter, while PNC Financial Services Group increased its stake over the same period. Additional new or expanded positions were reported by Russell Investments Group, BNP Paribas Financial Markets, and Sei Investments Co., reflecting continued engagement from asset managers with varying allocation sizes.

Zenas BioPharma is a clinical-stage biotechnology company focused on oncology and infectious disease programs. Founded in 2021 and headquartered in Cambridge, Massachusetts, the company applies structure-guided design and computational approaches to advance drug candidates from early discovery through clinical development.

ZBIO closed at USD 16.61 on January 05, 2026.